Last €45.59 EUR
Change Today +0.088 / 0.19%
Volume 0.0
As of 3:00 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGDN) Snapshot

Open
€46.06
Previous Close
€45.50
Day High
€46.17
Day Low
€45.59
52 Week High
02/14/14 - €58.73
52 Week Low
09/27/13 - €29.81
Market Cap
944.8M
Average Volume 10 Days
50.0
EPS TTM
--
Shares Outstanding
20.7M
EX-Date
04/3/07
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS (LGDN)

ligand pharmaceuticals (LGDN) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals (LGDN) Details

Ligand Pharmaceuticals Incorporated, a biotechnology company, acquires and develops royalty revenue generating assets in the United States. Its late-stage development programs include Promacta, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Captisol-enabled Melphalan IV for the multiple myeloma transplant setting; Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis; and Nexterone, an injectable formulation. The company’s late-stage development programs that are in Phase III clinical trials comprise Captisol-enabled Noxafil-IV; MK-8931 Beta-Secretase Inhibitor program for the treatment of Alzheimer’s disease; Captisol-enabled Carbamazepine-IV for the management of acute seizure disorder for hospital or emergency settings; and Captisol-enabled Delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections. It also offers Sparsentan that is in Phase II clinical trials for kidney diseases; Lasofoxifene, an estrogen partial agonist for osteoporosis treatment and other diseases; and Captisol-enabled Topiramate Injection, which is in Phase I clinical trials for the treatment of partial onset or primary generalized tonic-clonic seizures. In addition, the company’s preclinical stage products include HepDirect for liver diseases; Oral Human Granulocyte Colony Stimulating Factor for the treatment of Neutropenia; and IRAK4 Inhibitor for inflammation. Further, it provides Glucagon Receptor Antagonist that is in Phase I clinical trials for diabetes; Selective Androgen Receptor Modulator, which is in Phase II clinical trials for the therapeutic benefits; and Captisol-Enabled Clopidogrel that is in Phase III clinical trials for anti-coagulants. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.

20 Employees
Last Reported Date: 02/24/14
Founded in 1987

ligand pharmaceuticals (LGDN) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $500.3K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $294.6K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $368.1K
Vice President, General Counsel and Secretary
Total Annual Compensation: $283.4K
Compensation as of Fiscal Year 2013.

ligand pharmaceuticals (LGDN) Key Developments

GlaxoSmithKline Announces the Start of Phase 3 Study with Eltrombopag in Patients with Myelodysplastic Syndromes

Ligand Pharmaceuticals Incorporated announced that its partner GlaxoSmithKline (GSK) plc has started a phase 3 study to evaluate the platelet supportive care effects of eltrombopag (Promacta(TM)/Revolade(TM)) in combination with azacitidine (the current standard of care) versus placebo in combination with azacitidine in intermediate-1, intermediate-2 or high-risk patients with myelodysplastic syndromes (MDS). The global SUPPORT (TRC112121) study will assess the proportion of patients who are platelet transfusion free during the first four cycles of treatment. MDS is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or bone marrow. The disease usually manifests itself with one or more cytopenias, or reductions in the number of blood cells, and patients typically present with complications related to anemia (fatigue), neutropenia (infections) or thrombocytopenia (bleeding). MDS may evolve into acute myeloid leukemia (AML) in up to 45% of patients.

Ligand Pharmaceuticals Incorporated Signs Global License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors. The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases. Under the terms of the agreement, Ligand is entitled to receive 125,000 shares of TG Therapeutics common stock, valued at approximately $1 million at date of signing, and is eligible to receive $207 million in potential milestone payments. Ligand is also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.

Ligand Announces Presentation of Positive Data from Phase 1 Study on the Effect of the SERM Lasofoxifene to Increase Testosterone Levels in Men

Ligand Pharmaceuticals Incorporated announced that data from a Phase 1 study of the selective estrogen receptor modulator (SERM) lasofoxifene were featured in a poster presentation at ICE/ENDO 2014 in Chicago. The presentation provided data from a first-in-human clinical study of lasofoxifene that was performed by Pfizer and recently analyzed by Ligand demonstrating the potent and prolonged effect of a single dose to increase circulating testosterone and gonadotropin levels in healthy young men. Highlights of the presentation include: In an investigator-blinded, randomized, placebo-controlled, single-ascending dose study involving 36 healthy male volunteers, lasofoxifene was well-absorbed after oral administration with peak plasma concentrations reached approximately 6 to 9 hours post-dose and a long elimination half-life of approximately 106 hours. There were no serious adverse events and no clinically significant changes in safety laboratory, vital signs or ECG assessments. Single oral doses of lasofoxifene of 1, 3, 10, 30 and 100 mg increased levels of testosterone (T); doses of 30 and 100 mg increased levels of T by more than 80%. Levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were also elevated with single oral doses of 30 and 100 mg. Levels of T, LH and FSH peaked between 3 and 7 days post-dose and elevations induced by higher doses were maintained through at least 28 days. T levels plateaued at the high normal range of 30-40 nmol/L between 7 and 28 days post-dose regardless of lasofoxifene dose or LH levels.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGDN:GR €45.59 EUR +0.088

LGDN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LGDN.
View Industry Companies
 

Industry Analysis

LGDN

Industry Average

Valuation LGDN Industry Range
Price/Earnings 100.0x
Price/Sales 24.2x
Price/Book 20.0x
Price/Cash Flow 108.0x
TEV/Sales 23.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.